When compared to the efficacy data for mRNA-based coronavirus vaccines developed by Modern (NASDAQ: MRNA) and Pfizer (NYSE: PFE), which has been shown to be about 95% effective in keeping coronavirus infections under control, Johnson & Johnson’s (NYSE: JNJ) the vaccine results may not have inspired much optimism. The company’s adenovirus vector vaccine has been shown to be 66% effective in preventing moderate to severe COVID-19 in phase 3 studies.
But when we take a closer look, the vaccine data is incredibly promising. Not to mention that there are many logistical reasons why a single dose vaccine can be a big winner. Johnson & Johnson has promised not to profit from its vaccine during the pandemic, but once the public health crisis subsides, there may still be spoils for the health giant. See why “66%” is not the red flag you imagine.